Form4insider filings, from the source

SEC Form 4 · accession 0000919574-17-006322

Avalo Therapeutics, Inc. · AVTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
ARMISTICE CAPITAL, LLC
Director · 10% Owner
Steven Boyd
Director · 10% Owner
Period of report
Aug 17, 2017
Accepted (ET)
Aug 21, 2017 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Aug 17, 2017P26,002$0.5863A15,668,302D
Common StockF2Aug 17, 2017P26,002$0.5863A15,668,302ISee Footnote
Common StockF2Aug 17, 2017P26,002$0.5863A15,668,302ISee Footnote
Common StockF1Aug 18, 2017P31,698$0.6091A15,700,000D
Common StockF2Aug 18, 2017P31,698$0.6091A15,700,000ISee Footnote
Common StockF2Aug 18, 2017P31,698$0.6091A15,700,000ISee Footnote
Common StockF1Aug 21, 2017P15,564$0.6126A15,715,564D
Common StockF2Aug 21, 2017P15,564$0.6126A15,715,564ISee Footnote
Common StockF2Aug 21, 2017P15,564$0.6126A15,715,564ISee Footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
WARRANTSF1,F3$0.40holding————Jun 30, 2022COMMON STOCK14,285,71414,285,714D
WARRANTSF2,F3$0.40holding————Jun 30, 2022COMMON STOCK14,285,71414,285,714I
WARRANTSF2,F3$0.40holding————Jun 30, 2022COMMON STOCK14,285,71414,285,714I

Explanation of responses